Science

Arndt Vogel: First-in-Class EGFR-Directed KRAS G12V Inhibitor Shows Activity in Multiple Cancer Models

Arndt Vogel/X

Jun 22, 2025, 06:10

Arndt Vogel: First-in-Class EGFR-Directed KRAS G12V Inhibitor Shows Activity in Multiple Cancer Models

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X about a paper by Chad V. Pecot et al. published in Cancer Cell:

“A first-in-class EGFR-directed KRAS G12V selective inhibitor in Cancer Cell

EFTX-G12V selectively targets KRAS G12V while sparing wild-type KRAS

Activity in lung, colon, and PDAC cancer models

Very interesting MOA, KRAS is becoming draggable.”

Title: A first-in-class EGFR-directed KRAS G12V selective inhibitor

Authors: Lyla J. Stanland, Hayden P. Huggins, Snehasudha S. Sahoo, Alessandro Porrello, Yogitha Chareddy, Salma H. Azam, Jillian L. Perry, Pradeep S. Pallan, Kristina Whately, Lincy Edatt, William D. Green, Matthew C. Fleming, Jonah Im, Christina Gutierrez-Ford, Imani Simmons, Alyaa Dawoud, Katherine I. Zhou, Vandanaa Jayaprakash, Rani S. Sellers, Gabriela de la Cruz, Albert Wielgus, Justin Milner, Martin Egli, Albert A. Bowers, Chad V. Pecot.

You can read the Full Article in Cancer Cell.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Science

OncoDaily

Science

Arndt Vogel: First-in-Class EGFR-Directed KRAS G12V Inhibitor Shows Activity in Multiple Cancer Models

“A first-in-class EGFR-directed KRAS G12V selective inhibitor in Cancer Cell

EFTX-G12V selectively targets KRAS G12V while sparing wild-type KRAS

Activity in lung, colon, and PDAC cancer models

Very interesting MOA, KRAS is becoming draggable.”